PTGS2 and breast cancer: NF-κB p65, also known as RelA, and COX2 expressions were also significantly downregulated after TPPP3 silencing, indicating that interfering with TPPP3 alters the malignant phenotype of breast cancer by downregulating the NF-κB/COX2 pathways (Figure 2C).